Ublituximab is an investigational targeted B-cell therapy that shows superior efficacy when compared with teriflunomide, a commonly prescribed oral treatment...
– Investigational New Drug Application for CNTY-101, a CAR-iNK product candidate targeting CD19 for B-cell malignancies, cleared by FDA – – First...
Patient denied testing for weeks due to risk of physician infection & non-MSM status Amerimmune Long COVID Panel and Provista...
First TIL Therapy BLA Submission Initiated with U.S. Food and Drug Administration Complete BLA Submission on Track for Fourth Quarter...
RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the U.S....
WAYNE, Pa., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing...
– Company boasts highest second quarter sales to date; Q2 2022 sales of $5,500,000 vs $4,409,000 in Q2 2021, a...
August 29 webinar will detail the research and success of the clinical trial from the Sagol CenterORLANDO, Fla., Aug. 24,...
SAN CARLOS, Calif., Aug. 24, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced planned poster presentations at three...
- Neuroendocrine Prostate Cancer is Growing Unmet Medical Need - NEW YORK, Aug. 24, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences...
IRVINE, Calif., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to...
Virtual event on Wednesday, September 7 at 4:30 PM ET will feature key opinion leader (KOL) David Hong, M.D., from...
Sepsis Phase II protocol amendments have been cleared by regulatory authorities in Israel, Spain, and Greece. In addition to these...
33% improved by one fibrosis stage without worsening of NASH; 25% of patients treated with efruxifermin showed NASH resolution Consistent...
Oral presentation will feature results from Part A of the Phase 2/3 RINGSIDE clinical studyREHOVOT, Israel and WILMINGTON, Del., Aug....
Glycerol monolaurate has the potential to deliver broad antimicrobial activity to treat a variety of bacterial, fungal, and viral vaginal...
Patient relationship management and contact center technology enables Science 37 to achieve significantly greater patient engagementRESEARCH TRIANGLE PARK, N.C., Aug....
Results indicate significant decrease in cocaine craving in a sub-group that received the treatment TEL AVIV, Israel, Aug. 24, 2022...
Presentation will highlight opportunity for oral difelikefalin to address a significant unmet need in the treatment of pruritus in patients...
COMPANY ANNOUNCEMENT – NO. 36 / 2022 Copenhagen, DK and Boston, MA, August 24, 2022 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078), a biotechnology company...